Panel Discussion

Segment 8: Pathways as a Means to Deliver High-Value Care
April 27, 2016 – 
Expanding the definition of "value" beyond cost, Robert Dubois, MD, PhD, emphasized that clinical pathways need more dynamic quality metrics that provide more than just a snapshot of a patient's performance.
Segment 7: How Flexible Are Oncology Care Pathways?
April 27, 2016 – 
Panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.
Segment 6: Standardizing Clinical Pathways Across Health Plans
April 27, 2016 – 
While providers would be relieved of their administrative burden, standardizing care pathways across health plans may not be an easy task, Blase Polite, MD, MPP, explains.
Segment 5: Clinical Pathways - A Shared Decision-Making Tool?
April 27, 2016 – 
Have clinical pathways in oncology developed enough for providers and patients to use them as a shared decision-making tool? Panelists provide insight.
Segment 4: How Rigorous Should Pathway Development Be?
April 27, 2016 – 
Experts discuss the need for guidelines and adequate rigor when developing a care pathway in oncology.
Segment 3: Considerations for Developing a Clinical Pathway
April 27, 2016 – 
What do pathway developers consider as they formulate cancer clinical pathways? Panelists explain.
Segment 2: What Are Oncology Care Pathways?
April 27, 2016 – 
Panel members provide their own perspective on what clinical pathways encompass.
Segment 1: Introduction of Panel Members
April 26, 2016 – 
The American Journal of Managed Care convened an expert panel to discuss the development and utility of clinical pathways in oncology care.
Segment 13: Making HCV Care Sustainable for All Patients
February 12, 2015 – 
Looking at the situation in hepatitis C and its potential impact on other conditions from a provider standpoint, Ed Cohen, PharmD, FAPhA, offers up many questions to which there may not be answers just yet.
Segment 12: A New Precedent for Healthcare
February 12, 2015 – 
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome to the new and improved, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!